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ABSTRACT
Type 1 diabetes (T1D), an insulin-dependent diabetes, is considered to be an 
autoimmune disease. The cause of T1D is the destruction of insulin-producing ȕ-
cells in the pancreatic islets and thus lifelong insulin treatment is necessary. The 
pancreatic islets are infiltrated with the cells of the immune system and the 
destruction is considered to be T-cell-mediated. The autoimmune nature of T1D is 
characterized by the presence of autoreactive T-cells and autoantibodies against ȕ-
cell molecules in the circulation of the patients. Autoantibodies to islet cells and to 
islet cell derived autoantigens, such as insulin, are used together with genetic 
screening in the prediction of the disease. Insulin is the only ȕ-cell-specific 
autoantigen associated with T1D but the insulin autoantibodies (IAAs) are difficult 
to measure with proper sensitivity. T-cell assays for detection of autoreactive T-
cells, such as insulin-specific T-cells, have also proven to be difficult to perform. 
The genetic risk of T1D is associated with the human leukocyte antigen (HLA) class 
II gene region as is many other autoimmune diseases. However, genetic risk is only 
part of the risk of developing T1D: environmental factors also play an important 
role. The most studied environmental risk factors of T1D are enteroviruses and 
cow’s milk. Both of these factors affect the immune system through the gut and 
there is increasing evidence suggesting that the gut immune system plays a role in 
the development of T1D. One hypothesis is that the insulin-specific immune 
response develops against bovine insulin in cow’s milk during early infancy and 
later spreads to include human insulin, developing into a condition with 
autoaggressive characteristics. 
The aims of this study were to determine whether the separation of immunoglobulin 
(Ig)G from plasma would improve the sensitivity of the IAA assay and how insulin 
treatment affects the cellular immune response to insulin in newly diagnosed 
patients. Furthermore, the effect of insulin concentration in mother’s breast milk on 
the development of antibodies to dietary insulin in the child was also examined. 
Small intestinal biopsies were also obtained from children with T1D to characterize 
any immunological changes associated with T1D in the gut. 
The isolation of the IgG fraction from the plasma of T1D patients negative for 
plasma IAAs led to detectable IAA levels that exceeded those in the control children. 
Thus the isolation of IgG and dissociation of immune complexes may improve the 
sensitivity of the IAA assay. 
The effect of insulin treatment on insulin-specific T-cells was studied by culturing 
peripheral blood mononuclear cells in vitro with both human and bovine insulin. 
The insulin stimulation in vitro induced higher expression of regulatory T-cell 
markers at the messenger ribonucleic acid (mRNA) level in those patients treated 
with insulin than in patients examined before initiating insulin treatment. The 
insulin-induced expression of the regulatory T-cell marker Foxp3 was also 
demonstrated at the protein level. This finding suggests that insulin treatment in 
patients with T1D stimulates regulatory T-cells in vivo and this may partly explain 
the difficulties in measuring autoantigen-specific T-cell responses in recently 
diagnosed patients. The stimulation of regulatory T-cells by insulin treatment may 
also explain the remission period often seen after initiating insulin treatment. 
In the third study we showed that the insulin concentration in breast milk is 
increased in mothers affected with T1D. The insulin concentration in mother’s 
breast milk also correlated inversely with the levels of bovine insulin-specific 
antibodies in those children who were exposed to cow’s milk proteins in their diet. 
This finding suggests that human insulin in breast milk induces tolerance to dietary 
bovine insulin. However, in infants who later developed T1D-associated 
autoantibodies, the insulin concentration in their mother’s breast milk was increased. 
This finding may indicate that in those children prone to ȕ-cell autoimmunity, breast 
milk insulin does not promote tolerance to insulin but may in contrast enhance 
insulin-specific immunity. 
In the small intestinal biopsies the presence of several immunological markers, 
including markers for effector and regulatory T-cells, were quantified with the 
reverse transcriptase-polymerase chain reaction (RT-PCR). From these markers the 
expression of the interleukin (IL)-18 cytokine was significantly increased in the gut 
in patients with T1D compared with children with celiac disease or control children. 
The expression of regulatory T-cell markers in the intestine was not increased in 
children with T1D despite the presence of low-grade inflammation. The increased 
IL-18 expression lends further support for the hypothesis that the gut immune 
system is involved in the pathogenesis of T1D, whereas no activation of regulatory 
T-cells is seen in the intestinal immune activation related to T1D. 
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TIIVISTELMÄ 
Tyypin 1 diabetestä (T1D) eli insuliiniriippuvaista diabetestä pidetään autoimmuuni-
tautina, jossa puolustusjärjestelmän solut hyökkäävät kehon omia rakenteita vastaan. 
T1D:n syy on haimasaarekkeissa olevien insuliinia tuottavien ȕ-solujen tuhoutu-
minen ja siksi elinikäinen insuliinihoito on tarpeen. Immuunijärjestelmän solut tun-
keutuvat haimasaarekkeisiin ja solujen tuhoutumista pidetään T-solujen välittämänä 
tapahtumana. T1D:n autoimmuunista luonnetta kuvaa ȕ-solujen molekyylejä tunnis-
tavien autoreaktiivisten T-solujen ja autovasta-aineiden läsnäolo potilaiden veren-
kierrossa. Autovasta-aineita saarekesoluja ja saarekeperäisiä autoantigeeneja, kuten 
insuliinia, kohtaan käytetään yhdessä geneettisen kartoituksen kanssa taudin ennus-
tamiseen. Insuliini on ainoa ȕ-soluille spesifinen T1D:een liittyvä autoantigeeni, 
mutta insuliiniautovasta-aine (IAA) määritykseen liittyy ongelmia, esimerkiksi 
herkkyys jää usein heikoksi. Myös T-solumenetelmät autoreaktiivisten T-solujen, 
kuten insuliinispesifisten T-solujen, mittaamiseksi ovat osoittautuneet hankaliksi. 
T1D:n geneettinen riski liittyy HLA luokka II:n geenialueeseen kuten monella muul-
lakin autoimmuunitaudilla. Kuitenkin geneettinen riski muodostaa vain osan riskistä 
sairastua T1D:een: ympäristötekijöillä on myös tärkeä merkitys. Tutkituimmat 
T1D:n ympäristön riskitekijät ovat enterovirusinfektiot ja altistuminen lehmän mai-
dolle varhaislapsuudessa. Molemmat näistä tekijöistä vaikuttavat suoliston puolus-
tusjärjestelmään ja tutkimuksissa onkin enenevässä määrin todisteita viitaten siihen, 
että suoliston immuunijärjestelmä näyttelee osaa T1D:n kehittymisessä. Yksi hypo-
teesi on, että insuliinispesifinen immuunivaste kehittyy lehmän maidon naudan insu-
liinia kohtaan varhaislapsuudessa ja insuliinispesifinen immuunivaste myöhemmin 
laajenee kattamaan myös ihmisen insuliinin ja kehittyy aggressiiviseksi auto-
immuunivasteeksi. 
Tämän tutkimuksen tavoitteina oli tutkia parantaisiko immunoglobuliini (Ig) G:n 
erottaminen plasmasta IAA-menetelmän herkkyyttä ja selvittää kuinka insuliinihoito 
vaikuttaa soluvälitteiseen immuunivasteeseen insuliinia kohtaan juuri diagno-
soiduilla potilailla. Lisäksi äidin rintamaidon insuliinipitoisuuden vaikutusta lapsen 
insuliinivasta-aineiden kehittymiseen tutkittiin. Myös ohutsuolen koepaloja kerättiin 
T1D:stä sairastavilta lapsilta löytääksemme T1D:een liittyviä immunologisia muu-
toksia suolessa. 
IgG:n erottaminen T1D-potilaiden, jotka olivat plasmaltaan IAA negatiivisia, 
plasmasta johti mitattaviin IAA -tasoihin, jotka olivat korkeammat kuin kontrolli-
lapsilla. Siksi IgG:n eristäminen ja immuunikompleksien hajottaminen saattaisi 
parantaa IAA-menetelmän herkkyyttä. 
Insuliinihoidon vaikutusta insuliinispesifisiin T-soluihin tutkittiin viljelemällä 
perifeerisen veren mononukleaarisoluja in vitro sekä ihmisen että naudan insuliinin 
kanssa. Insuliinistimulaatio in vitro aiheutti korkeamman säätelevien T-solujen 
merkkiaineiden ekspression lähetti-RNA-tasolla niillä potilailla, jotka olivat saaneet 
insuliinihoitoa kuin niillä, jotka tutkittiin ennen insuliinihoidon aloittamista. 
Insuliinin aiheuttama säätelevien T-solujen merkkiaineen Foxp3:n ilmentyminen 
osoitettiin myös valkuaisainetasolla. Tämä löydös viittaa siihen, että insuliinihoito 
T1D-potilailla stimuloi sääteleviä T-soluja in vivo ja tämä saattaa selittää osittain 
vaikeudet mitata autoantigeenispesifisiä T-soluvasteita juuri diagnosoiduilla 
potilailla. Insuliinihoidon aiheuttama säätelevien T-solujen stimulaatio saattaa myös 
selittää insuliinihoidon jälkeisen remissiovaiheen. 
Kolmannessa työssä osoitimme, että äidinmaidon insuliinipitoisuus on koholla 
T1D:tä sairastavilla äideillä. Myös äidin rintamaidon insuliinipitoisuus korreloi 
käänteisesti naudan insuliinille spesifisiin vasta-aineisiin niillä lapsilla, jotka olivat 
ruokavaliossaan altistuneet lehmän maidon valkuaisaineille. Tämä löydös viittaa 
siihen, että ihmisen insuliini rintamaidossa saa aikaan sietokykyä ravinnon naudan 
insuliinia kohtaan. Kuitenkin lasten, jotka myöhemmin kehittivät T1D:een liittyviä 
autovasta-aineita, äitien rintamaidossa oli insuliinipitoisuus koholla. Tämä löydös 
saattaa tarkoittaa sitä, että lapsilla, jotka ovat alttiita autoimmuniteetille ȕ-soluja 
kohtaan, rintamaidon insuliini ei saakaan aikaan sietokykyä, vaan voi jopa lisätä 
insuliinispesifistä immuunivastetta. 
Ohutsuolen koepaloista kvantitoitiin useiden immunologisten merkkiaineiden, kuten 
erilaisten T-solujen merkkiaineiden, esiintymistä  käänteistranskriptaasi-polymeraasi-
ketjureaktiolla (RT-PCR). Näistä merkkiaineista interleukiini (IL) -18 sytokiinin 
ekspressio oli merkittävästi lisääntynyt suolessa T1D-potilailla verrattuna keliakiaa 
sairastaviin lapsiin ja kontrollilapsiin. Sen sijaan emme havainneet säätelevien T-
solujen merkkiaineiden lisääntynyttä ilmentymistä T1D-potilaiden suolinäytteissä. 
Lisääntynyt IL-18:n ekspressio tuo lisätodisteen sen hypoteesin puolesta, että suolen 
immuunijärjestelmän aktivaatio liittyy T1D:n patogeneesiin, mutta säätelevien T-
solujen aktivaatiota ei T1D:een liittyvässä suolen tulehduksessa nähdä. 
Avainsanat: tyypin 1 diabetes, insuliini, säätelevät T-solut, suoli
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1 INTRODUCTION
The first document referring to a medical state resembling diabetes mellitus dates 
back to 1552 BC in Egypt: the Ebers Papyrus. The first descriptions of sugar in the 
urine of patients were already found in Hindu medicine around 500 AD, but in 1674 
T. Willis in England sparked new interest in diabetes by finding the sweet taste in 
the urine of patients with diabetes mellitus. In 1776 M. Dobson in England also 
found sugar in the blood of diabetic patients. 
Minkowski and von Mering from the University of Strasbourg found in 1889 that 
removal of the pancreas from a dog results in diabetes. In 1908 treatment was 
attempted, using a substance extracted from the pancreas and injected into patients, 
causing reduced levels of sugar. In 1921 insulin was isolated from a dog´s pancreas 
and one year later insulin was used successfully to treat a diabetic teenager in 
Toronto. This medical achievement was recognized by granting the Nobel Prize to 
Banting and MacLeod in 1923, a year that also saw the beginning of commercial 
production of insulin. 
In 1936 Himsworth suggested that diabetes mellitus falls into two types, and type 1 
and type 2 diabetes have been formally recognized since 1979. (History of Diabetes 
adapted from http://www-unix.oit.umass.edu/∼abhu000/diabetes/index.html) Type 1 
diabetes (T1D), diagnosed during childhood or adolescence, comprises 5-10% of all 
diabetes mellitus cases. The autoimmune nature of T1D was proposed in 1965 by 
Gepts and further confirmed during the 1970s when susceptibility to the disease was 
associated with the human leukocyte antigen (HLA) gene region, and islet cell-
specific autoantibodies and autoreactive T-cells were proven to exist. However, in 
the 21st century the pathogenesis of T1D remains unknown. 
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2 REVIEW OF THE LITERATURE 
2.1 Epidemiology of type 1 diabetes 
Diabetes is one of the most common chronic diseases in childhood and the 
prevalence of T1D is on the rise (Onkamo et al. 1999). The highest incidence of 
T1D in children  14 years of age is in Finland (Podar et al. 2001; Passa 2002). The 
incidence of T1D in Finland has increased since the mid-1960s by an average of 
2.8% per year (Tuomilehto et al. 1995). For example, in 1965 the incidence was 18 
per 100 000 children and increased to 48.5 per 100 000 children  14 years of age in 
1998 (Karvonen et al. 1999; Podar et al. 2001). 
There are geographical and ethnic differences in the incidence of T1D. A high 
incidence (> 20 per 100 000 per year in 1994) is found in Finland, Sardinia, 
Sweden, Norway, Portugal, the United Kingdom, Canada, and New Zealand 
(Karvonen et al. 2000). Moderately high incidences are found in the European 
countries and in the United States: e.g. the annual incidence in France was 9.3 
per 100 000 in 1995 (Passa 2002) and about 14.8 per 100 000 in 1994 in the 
United States (Karvonen et al. 2000). In Eastern Europe the incidence is less 
than in other parts of Europe; e.g. the incidence in Estonia is 2-4 times less than 
in the Nordic countries (Finland, Sweden, Norway) (Karvonen et al. 2000; Podar 
et al. 2001). The lowest incidence of T1D (< 1 per 100 000 per year) is found in 
China and in some areas of South America (Karvonen et al. 2000). A moderately 
low incidence of T1D (1-10 per 100 000 per year) is found in Asia (e.g. in Japan 
the incidence is about 1.5 per 100 000 per year [Abiru et al. 2002]), in South 
America (Aschner 2002), and in Africa (Motala 2002; Motala et al. 2003). 
Ethnic differences in T1D risk are found in multiracial populations (Diabetes 
Epidemiology Research International Group 1988; Aschner 2002). For example, 
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in the United States the incidence of T1D is lower among African-Americans 
and Hispanics than in white non-Hispanics. 
The incidence of T1D is globally increasing and the highest increase in incidence is 
in children under 5 years of age (Karvonen et al. 1999). In Europe the increase in 
incidence (from 1989 to 1994) in children 0-4 years of age was 6.3% while for those 
5-9 or 10-14 years of age the increases were 3.1% and 2.4%, respectively 
(EURODIAB ACE Study Group 2000). 
2.2 Classification of diabetes in children 
The cause of T1D is a deficiency in insulin secretion and thus lifelong insulin 
treatment is needed in patients with T1D. According to current classifications T1D 
is divided into two subclasses: type 1A diabetes and a rare type 1B diabetes (The 
Expert Committee on the Diagnosis and Classification of Diabetes Mellitus 2003; 
American Diabetes Association 2006). Type 1A diabetes results in cell-mediated 
autoimmune destruction of insulin-producing β-cells in the pancreatic islets. In these 
children the presence of peripheral autoantibodies is a marker of autoimmune 
destruction. Type 1A diabetes also has a strong HLA association. Type 1B diabetes 
is called idiopathic diabetes because the etiology of the β-cell destruction is not 
known. Patients with type 1B diabetes have no immunological evidence of β-cell 
autoimmunity and no HLA association. A Japanese group suggested that type 1B 
diabetes could be further divided into two groups (Imagawa et al. 2000a; Imagawa et 
al. 2000b). They refer to this novel type as fulminant T1D due to its very rapid 
onset. Usually the hyperglycemic symptoms last less than one week before the 
diagnosis. These patients have no autoimmune features in their serum or in the 
pancreatic islets. The fulminant type of T1D may comprise as much as 10% of the 
T1D patients in Japan but is very uncommon in caucasoid populations. 
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Immune-mediated T1D (type 1A) is the most common form of diabetes among 
children, comprising about 80% of cases worldwide (Rosenbloom et al. 1999). In 
addition to T1D there are some rare types of diabetes that are diagnosed during 
childhood or early adulthood (< 25 years of age). These forms are associated with 
monogenic defects in β-cell function (The Expert Committee on the Diagnosis and 
Classification of Diabetes Mellitus 2003; American Diabetes Association 2006). 
Maturity-onset diabetes of the young (MODY) is characterized by impaired 
insulin secretion and divided into its own subtypes according to specific genetic 
mutations (Mitchell and Frayling 2002). Another form of diabetes caused by a 
monogenic defect in β-cells is associated with a mutation in mitochondrial 
deoxyribonucleic acid (DNA) that affects insulin secretion in β-cells (Reardon et 
al. 1992; Kadowaki et al. 1994). This form of diabetes is maternally transmitted 
and often associated with deafness. Mitochondrial diabetes is found both in 
children and in adult-onset patients and the prevalence is about 1.5% of the 
diabetic population (Gerbitz et al. 1995). Maturity-onset diabetes of the young 
(MODY) is found mainly among Caucasian populations but mitochondrial 
diabetes is more prevalent in the Far East where the incidence of autoimmune T1D 
is very low. Diabetes may in some rare cases also be due to a genetic defect in 
insulin activity (American Diabetes Association 2006). These cases are associated 
with mutation of the insulin receptor gene and the symptoms vary from moderate 
hyperglycemia to severe diabetes. 
Type 2 diabetes, which results from insulin resistance with an insulin secretory 
defect, is known as a disease of adulthood, but recently the incidence of type 2 
diabetes has also increased among children and adolescents (Arslanian 2002; 
Ehtisham and Barrett 2004). It was estimated that in 1994 type 2 diabetes accounted 
for up to 16% of all new diabetes cases in adolescents in the United States (Pinhas-
Hamiel et al. 1996). Type 2 diabetes in youth is strongly associated with diet and 
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obesity and is much more frequent among particular ethnic groups such as African-
Americans, Native Americans, Mexican-Americans, and Arabs. 
2.3 Clinical features of autoimmune type 1 diabetes 
2.3.1 Diagnostic criteria 
The classic symptoms of diabetes include polyuria, polydipsia, and weight loss. If 
these symptoms are present, the plasma glucose concentration can be measured at 
any time of the day and a concentration  11.1 mmol/l is considered diabetic. If the 
glucose concentration is detected in fasting, a plasma sample of 7.0 mmol/l or over 
is diabetic. The diagnosis of diabetes can also be performed with an oral glucose 
tolerance test (OGTT) in which the glucose level should decline to under 11.1 
mmol/l within 2 h, but this test is not recommended for diagnosis of children who 
usually have more severe symptoms and are prone to very high blood glucose 
values. For an asymptomatic person the diabetic hyperglycemia should be measured 
on two or more separate occasions (The Expert Committee on the Diagnosis and 
Classification of Diabetes Mellitus 2003; American Diabetes Association 2006). 
Patients who have autoimmune type 1A diabetes are usually diagnosed at a 
young age (<14 years) with acute onset and are at risk for ketoacidosis at 
diagnosis. These patients are rarely obese, in multiracial populations are usually 
white, and most have circulating autoantibodies against β-cell antigens. Their 
plasma C-peptide levels are low, referring to very low insulin secretion, and no 
evidence of insulin resistance can be found. 
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2.3.2 Autoimmunity
The autoimmune features of T1D were first suggested in 1965 when Gepts described 
insulitis in the pancreatic islets of young patients with T1D (Gepts 1965). The word 
insulitis is used for the infiltration of cells of the immune system into the pancreatic 
islets. The infiltrating cells involve CD8-positive cytotoxic T-cells, CD4-positive 
helper T-cells (Th cells), macrophages and monocytes, natural killer cells, and B-
cells, of which the CD8-positive cells seem to predominate in the infiltrations 
(Bottazzo et al. 1985; Itoh et al. 1993). In 1974 the autoimmune nature of T1D 
became more evident when both autoantibodies and autoreactive T-cells against β-
cells were shown to exist in the circulation of patients with T1D (Bottazzo et al. 
1974; MacCuish et al. 1974a; MacCuish et al. 1974b). 
T1D is considered to be a T-cell-mediated autoimmune disease. A proportion of the 
T-cells infiltrating the pancreatic islets are activated, as shown by increased 
expression of HLA class II molecules and interleukin (IL)-2 receptors on their 
surface (Bottazzo et al. 1985). Similarly, the islet cells themselves express increased 
amounts of HLA class I molecules (Bottazzo et al. 1985; Foulis et al. 1987; Itoh et 
al. 1993). HLA class I and class II molecules are those molecules that present the 
antigenic epitopes to T-cells and bind to their coreceptors on cytotoxic (CD8+) and 
on Th (CD4+) cells, respectively. Furthermore, the major gene loci associated with 
risk of T1D are located within the HLA gene region (Singal and Blajchman 1973; 
Nerup et al. 1974). The disease can be transferred from a diabetic individual to an 
unaffected individual by autoreactive cells, as shown in a case report on transfer of 
T1D between siblings by bone marrow transplantation (Lampeter et al. 1993). 
Immunosuppressive drugs, which affect specifically T-cells, have a delaying effect 
on the disease course (Stiller et al. 1984; Bougnères et al. 1988). Treatment with 
monoclonal antibody against CD3, a molecule expressed in almost all T-cells, in 
recently diagnosed patients also maintains or improves the patient’s own insulin 
production for at least one year after the diagnosis (Herold et al. 2002). Most likely 
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the effect of this treatment is due to production of regulatory cells that are capable of 
suppressing autoreactive T-cells (reviewed by Harlan and von Herrath 2005). A 
report on the development of T1D in a patient with severe hereditary B-cell 
deficiency lends further support for the cellular immune response playing an 
important role (Martin et al. 2001). 
Although B-cells are not necessarily required for the development of T1D, 
autoantibodies to pancreatic islet cells and to individual T1D-associated 
autoantigens are widely used for the prediction of the disease (Mueller et al. 2002; 
Kulmala 2003). Patients with recent-onset T1D show humoral immune responses to 
as many as 14 different β-cell molecules (Lieberman and DiLorenzo 2003). T-cell 
responses has been demonstrated to seven of these autoantigens which include 
insulin (MacCuish et al. 1975), glutamate decarboxylase (GAD) 65 (Atkinson et al. 
1992), insulinoma-associated protein 2 (IA-2) (Durinovic-Bellò et al. 1996), heat-
shock proteins 60 and 70 (Abulafia-Lapid et al. 1999; Abulafia-Lapid et al. 2003), 
islet cell autoantigen of 69 kDa (ICA69) (Roep et al. 1996), and transcription factor 
jun-B (Honeyman et al. 1993). 
For the prediction of T1D only four assays are routinely used: islet cell antibodies 
(ICAs) are measured basically in the same way as reported in 1974 by using 
immunofluorescence labeling of frozen pancreatic sections (Bottazzo et al. 1974), 
insulin autoantibodies (IAAs) (Palmer et al. 1983), GAD autoantibodies (GADAs) 
(Baekkeskov et al. 1990; Rowley et al. 1992), and IA-2 autoantibodies (IA-2As) (Lan 
et al. 1996) are measured by radiobinding assays using radiolabeled antigens. In 
prediction a repeated appearance of multiple autoantibodies is associated with 
increased risk of T1D and if a subject who is positive for three or four autoantibodies 
carries the highest HLA risk genotype the risk of T1D is over 90% (Kulmala 2003). 
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2.4 Risk factors of type 1 diabetes 
2.4.1 Genetic risk 
More than 20 gene loci are associated with susceptibility to T1D (Maier and Wicker 
2005). The most important locus defining the risk of T1D is located within the HLA 
class II gene region and the HLA class II region can be estimated to be responsible 
for up to 50% of the genetic risk (Noble et al. 1996). Among the other genes three 
loci, whose effects are relatively modest on T1D susceptibility, were well 
characterized: the insulin gene (Bell et al. 1984), cytotoxic T-lymphocyte antigen-4 
(CTLA-4) gene (Nisticò et al. 1996) and PTPN22 gene (Bottini et al. 2004). 
According to the current view, the major factors for the genetic risk of T1D are 
HLA-DQA1 and HLA-DQB1. These two loci are in linkage disequilibrium and in 
most cases the characterization of HLA-DQB1 genes is enough to estimate the risk 
genotype (Ilonen et al. 2002). However, the genetic risk associated with the HLA 
class II gene region is more complicated and in addition to HLA-DQ the HLA-DR 
alleles, among others, have a modifying effect on the risk. 
The highest risk genotypes of T1D are DQA1*0301-DQB1*0302 (DQ8) and 
DQA1*0501-DQB1*0201 (DQ2) (Ilonen et al. 2002; Lambert et al. 2004). The 
highest risk is associated with the DQA1*0301-DQB1*0302/DQA1*0501-
DQB1*0201 heterozygote. In addition to the risk alleles, three alleles in the 
HLA-DQ gene region protect against T1D. These are DQB1*0602, 
DQB1*0301, and DQB1*0603, of which the DQB1*0602 allele has the 
strongest protective effect. 
The highest risk alleles, DQB1*0302 and/or DQB1*0201, are found in 90-95% 
of patients with T1D (Ilonen et al. 1996; Ilonen et al. 2002).  These risk alleles 
are also common in the general population: approximately 40-45% of Finns 
carry one of these alleles and half of them have no protective alleles (Ilonen et 
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al. 1996; Ilonen et al. 2002). However, the risk of a Finnish newborn of 
developing T1D is less than 1% (in 1998 the risk was 0.54%) (Hyttinen et al. 
2003) suggesting that environmental factors play a major role in the 
pathogenesis of T1D. 
2.4.2 Environmental risk factors 
2.4.2.1 Viruses
Several viruses have been connected with the risk of T1D but their role in 
pathogenesis has been difficult to prove. Congenital rubella infection leads to 
diabetes in about 20% of affected individuals and the virus is able to infect the fetal 
pancreas (Menser et al. 1978; Forrest et al. 2002). However, the rubella virus cannot 
be considered as a risk factor for T1D today, since rubella infections are almost 
nonexistent due to vaccination programs in developed countries. The same holds for 
the mumps virus which may also be associated with T1D (Kremer 1947) and which 
is able to infect human β-cells in vitro (Parkkonen et al. 1992). The other viruses 
occasionally connected with T1D include cytomegalovirus (Ward et al. 1979; Pak et 
al. 1988), Epstein-Barr virus (Nonaka et al. 1982) and retroviruses (Conrad et al. 
1997), but the evidence for their role in the pathogenesis of T1D is scanty. 
The most convincing candidates for viral triggers are the enteroviruses. 
Enteroviruses belong to the picornavirus family and comprise over 70 serotypes 
including polioviruses, coxsackieviruses A and B, echoviruses and several others 
(Lukashev 2005). Enteroviral infections are common during childhood and are 
transmitted through the fecal-oral route. The enteroviruses are resistant to acidic pH 
and bile and they pass through the stomach to the intestine. Viremic spread to other 
organs, such as the pancreas, can occur. In vitro studies showed that some 
enteroviruses are also able to infect β-cells (Yoon et al. 1978; Roivainen et al. 2000). 
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The first evidence for the association of enterovirus infection with T1D was in 1969 
when it was shown that patients with recent-onset T1D had higher antibody titers to 
coxsackieviruses, particularly coxsackievirus B4, than unaffected subjects (Gamble 
et al. 1969). Coxsackievirus B4 was also isolated from the pancreas of a child who 
died from diabetic ketoacidosis and this virus was able to cause diabetes in a mouse 
strain (Yoon et al. 1979). In addition to the increased antibody response to 
coxsackieviruses, increased viral ribonucleic acid (RNA) in blood (Clements et al. 
1995; Andréoletti et al. 1997) and cellular immune response to coxsackieviruses in 
patients with T1D were reported (Jones and Crosby 1996; Juhela et al. 2000). 
In follow-up studies of children with increased risk of T1D, findings of the 
association of coxsackieviruses with T1D are conflicting. In Finnish children the 
occurrence of coxsackievirus infections was more frequent, both in pregnant 
mothers whose children later developed T1D and in the siblings of affected children 
who were diagnosed with T1D in a follow-up study (Hyöty et al. 1995). 
Furthermore, the increased enterovirus antibody levels were clustered in the sample 
at intervals in which β-cell-specific antibodies first appeared (Hiltunen et al. 1997). 
However, a large Finnish study on the association of enterovirus infection during 
pregnancy and T1D in offspring did not support the hypothesis that T1D is due to 
maternal enterovirus infection (Viskari et al. 2002). The Australian and the German 
BabyDiab studies and the American DAISY study, birth-cohorts, also could confirm 
no association between coxsackieviruses and T1D (Honeyman et al. 2000; 
Füchtenbusch et al. 2001; Graves et al. 2003). The Australian BabyDiab study found 
instead a connection between the appearance or increase of T1D-associated 
autoantibodies and seroconversion of another virus, rotavirus (Honeyman et al. 
2000). The same research group also showed that rotavirus is able to infect animal 
pancreatic islets in vitro (Coulson et al. 2002), but no other group has been able to 
confirm the connection between rotavirus infection and T1D. 
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The hypothetic mechanisms by which the viruses could cause the destruction of 
pancreatic β-cells include both direct viral infection of β-cells, causing lytic 
destruction, and so-called bystander killing (reviewed by Filippi and von Herrath 
2005). The bystander killing hypothesis suggests that viral infection near β-cells 
would cause a release of immune mediators such as cytokines and nitric oxide which 
are harmful to β-cells, and the release of self-antigens from damaged β-cells could 
lead to activation of autoreactive T-cells. A third theory is molecular mimicry in 
which a viral antigenic epitope shares similarity with the self-protein expressed in β-
cells and the immune response to this viral epitope would spread to include the self-
antigen. Molecular mimicry may be involved in the association between both 
coxsackievirus B4 and rotavirus and T1D. P2-C protein of coxsackievirus B4 shares 
an amino acid sequence similar to that of GAD (Kaufman et al. 1992) and the VP7 
protein of rotavirus has similarity with both IA-2 and GAD (Honeyman et al. 1998). 
2.4.2.2 Dietary factors 
The first reports of the possible effect of a dietary component on the incidence of 
T1D were published in the early 1980s. In 1981 an Icelandic study suggested that 
the consumption of foods containing high amounts of N-nitrosocompounds, in this 
case smoked/cured mutton, at the time of conception was associated with the 
increased incidence of T1D in offspring (Helgason and Jonasson 1981). The effect 
of the smoked/cured mutton was later confirmed in an animal study (Helgason et al. 
1982). N-nitrosocompounds are also formed from dietary nitrate and nitrite in the 
gut by reaction with amines and amides. Nitrates and nitrites are found in meat 
products as food additives and nitrates also in vegetables. In a Swedish case-control 
study the child´s consumption of foods containing N-nitrosoamines or nitrates or 
nitrites was associated with increased risk of T1D (Dahlquist et al. 1990). In a 
Finnish study the daily dietary intake of nitrite was also greater in children with T1D 
and their mothers compared with control children and their mothers (Virtanen et al. 
1994). However, a case-control study from Canada could find no association 
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between the consumption of particular nitrite- and nitrate-containing meat products 
and the incidence of T1D (Siemiatycki et al. 1989). 
In the 1980s it was shown that manipulation of the protein source in the diet of Bio-
Breeding rats, one of the animal models of T1D, also affects the disease process. 
Elliott and Martin (1984) reduced the incidence of diabetes in Bio-Breeding rats 
from 50% to 15% by replacing whole proteins with amino acids. Furthermore, when 
1% milk powder was added to the manipulated amino acid diet the incidence of 
diabetes was restored to 52%. Later the protective effect of the amino acid -based 
diet was also shown in another animal model of T1D, non-obese diabetic (NOD) 
mice (Elliott et al. 1988; Coleman et al. 1990). Elliott et al. (1988) showed that the 
addition of intact lactic casein in the amino acid -based diet increased the incidence 
of diabetes, but in the study of Coleman et al. (1990) intact casein or addition of 
skim milk to the diet did not have this diabetogenic effect. These animal studies and 
that of Borch-Johnsen et al. (1984), showing an inverse correlation between the 
duration of breast-feeding and the incidence of T1D, initiated studies on the 
association of cow’s milk with the incidence of T1D. 
Since the first report on the association of breast-feeding and T1D, several studies 
have been published, both for and against (reviewed by Virtanen and Knip 2003). It 
is worth mentioning that in a large Finnish multivariate analysis, all the association 
of T1D with the duration of breast-feeding was explained by its correlation with 
cow’s milk exposure, suggesting that early exposure to cow’s milk proteins, and not 
the protective effect of breast-feeding, is the pivotal factor (Virtanen et al. 1993). 
Two reports were published on the association of cow’s milk consumption in the 
population with the incidence of T1D in several countries: both found a positive 
correlation (Scott 1990; Dahl-Jorgensen et al. 1991). However, these population-
based case-control studies on cow’s milk consumption are inconsistent. In a Swedish 
study the frequency of milk intake was lower in diabetic children (Dahlquist et al. 
1990) but in the Australian and Finnish studies the consumption of cow’s milk was 
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higher in children who developed T1D or in the Finnish study developed T1D-
associated autoantibodies (Verge et al. 1994; Virtanen et al. 1998). 
Three birth-cohorts, the American DAISY and both Australian and German 
BabyDiab studies, found no association between breast-feeding or the age of 
exposure to cow’s milk with the development of T1D-associated autoantibodies 
(Norris et al. 1996; Couper et al. 1999; Hummel et al. 2000). In the Finnish DIPP 
study, however, infants who were exclusively breast-fed for at least 4 months or 
who were first exposed to cow’s milk at 4 months of age or older had lower risk of 
developing IA-2As or all four autoantibodies measured (ICAs, IA-2As, GADAs and 
IAAs) (Kimpimäki et al. 2001a). However, in another study from the DIPP case-
control cohort, no association with the duration of breast-feeding and ȕ-cell
autoimmunity was seen (Virtanen et al. 2006). Based on findings in the case-control 
studies, an intervention study for primary prevention of T1D, the TRIGR (Trial to 
Reduce IDDM in the Genetically at Risk) study, has been initiated. The TRIGR pilot 
study showed that children with increased risk for T1D (children having a relative 
with T1D and a risk HLA genotype) generated somewhat lower amounts of T1D-
associated autoantibodies if they had received casein hydrolysate -based infant 
formula in early childhood instead of conventional formula containing intact cow’s 
milk proteins (Åkerblom et al. 2005). 
Furthermore, it was shown that children with T1D in Finland, Sweden, and Hungary 
have increased levels of antibodies to cow’s milk and to β-lactoglobulin, a protein 
included in cow’s milk but not in human milk (Savilahti et al. 1988; Dahlquist et al. 
1992; Saukkonen et al. 1996). The cellular immune response to the cow’s milk 
proteins β-lactoglobulin and β-casein is also increased in patients with newly 
diagnosed T1D (Cavallo et al. 1996; Vaarala et al. 1996). These findings may be due 
to either altered consumption of cow’s milk or altered immunological response to 
cow’s milk proteins, or increased permeability of the intestine to dietary proteins in 
children who develop T1D. 
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The other dietary factors studied in association with T1D include, among others, 
vitamin D deficiency and exposure to some plant proteins such as cereal gluten. 
Treatment with the active form of vitamin D, 1,25 dihydroxyvitamin D3, can prevent 
diabetes in NOD mice (Mathieu et al. 1992; Mathieu et al. 1994). It was also 
reported that adequate vitamin D supplementation in infancy is associated with 
decreased frequency of T1D both in a multicenter trial involving seven European 
centers and in a Finnish birth-cohort (The EURODIAB Substudy 2 Study Group 
1999; Hyppönen et al. 2001). 
Gluten, a protein found in wheat, rye, and barley, is the target protein in celiac 
disease (reviewed by Jabri and Sollid 2006). An increased prevalence of celiac 
disease in children with T1D was reported (Mäki et al. 1984; Savilahti et al. 1986; 
Not et al. 2001) and this may be caused partly by the association of celiac disease 
with the HLA-DQB1*02 genotype which is the other risk allele for T1D. A wheat-
based diet can be diabetogenic in rodent models of autoimmune diabetes and in a 
multicenter trial involving both Bio-Breeding rats and NOD mice the highest 
incidence of diabetes occurred in rodents fed with a milk-free, wheat-based diet 
(Beales et al. 2002). Catassi et al. (1987) showed as early as in the 1980s the 
presence of an increased celiac disease -associated antibody titer in children with 
recent-onset T1D. Similar findings of increased humoral immune response to celiac 
disease -associated antigens have also been published since (Bao et al. 1999; 
Lampasona et al. 1999). Furthermore, patients with newly diagnosed T1D have 
enhanced cellular immune response to wheat gluten (Klemetti et al. 1998) and 
patients with T1D have increased antibody response to the wheat storage protein, 
Glb1 (MacFarlane et al. 2003). In a German birth-cohort, exposure to gluten-
containing food before the age of 3 months was associated with the development of 
ȕ-cell autoantibodies (Ziegler et al. 2003) and in the American DAISY study too 
early (before 4 months of age) and too late (7 months or older) exposures to cereals 
were associated with an increased risk of β-cell autoimmunity (Norris et al. 2003). 
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Several mechanisms by which dietary components could affect the pathogenesis of 
T1D have been proposed. The regulation of the gut immune system and oral 
tolerance may be disturbed in patients with T1D and this hypothesis would fit with 
the enhanced immune response to dietary proteins found in cow’s milk and cereal. 
We have also proposed a hypothesis that exposure to cow’s milk could lead to 
immunization to bovine insulin. Bovine insulin differs from human insulin by only 
three amino acids and the immune response to insulin could spread to involve 
human insulin as well (Vaarala et al. 1998). It cannot be ruled out that the various 
environmental factors could interact, e.g. breast-feeding could protect from enteric 
infections as well as enteric infections could increase the immunity to dietary 
antigens by changing the mucosal immunity. It was shown that children who had 
cellular immune responses to enteroviruses at 3 months of age had higher humoral 
immune responses to bovine insulin at 6 and 9 months of age (Vaarala et al. 2002). 
Vitamin D affects immune cells (Rigby 1988) and reduced levels of vitamin D may 
enhance anti-viral T-cell responses. In one study Dahlquist et al. (1991) also showed 
that the frequency of infections and a high intake of foods containing nitrosoamines 
tended to interact. 
2.5 Role of the gut immune system in type 1 diabetes 
The most studied environmental factors associated with T1D, enteroviruses and diet, 
both affect through gut. Gut-associated lymphoid tissue (GALT) is the largest part 
of the entire immune system. It encounters huge amounts of various nonself 
particles derived from the diet and microorganisms all the time and its major role is 
to distinguish between advantageous and harmful nonself molecules. The gut-
associated lymphoid tissue (GALT) achieves oral tolerance to useful dietary 
components and to favorable microflora but still develops a proper immune response 
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against harmful toxins and pathogens (reviewed by Dubois et al. 2005; Macdonald 
and Monteleone 2005). 
Evidence supporting the view that disturbances in the gut immune system are 
involved in the pathogenesis of T1D is increasing. As mentioned earlier the diet 
influences the incidence of autoimmune diabetes in animal models of T1D (Elliott 
and Martin 1984; Elliott et al. 1988; Coleman et al. 1990). Furthermore gluten-
containing, diabetes-promoting diets result in reduced villous height and increased 
infiltration of T-cells in the small intestine of NOD mice (Maurano et al. 2005) and 
increased proportions of Th1 cells in the mesenteric lymph nodes of Bio-Breeding 
rats (Chakir et al. 2005). However, it was also shown that enteropathy, as assessed 
by increased crypt length, increased proliferative activity of crypt epithelial cells, 
and increased number of lymphocytes in the mucosae, is present in Bio-Breeding 
rats soon after weaning despite the consistency of the diet (Graham et al. 2004). 
Furthermore, the development of insulitis and diabetes can be prevented by early 
oral administration of probiotics (nonpathogenic, favorable bacteria able to prevent 
colonization of harmful bacteria) in NOD mice (Calcinaro et al. 2005).  
A significant amount of the lymphocytes infiltrating the pancreatic islets express 
α4β7-integrin, a gut-homing receptor, and also its counterreceptor, mucosal 
addressin cell adhesion molecule-1 (MAdCAM-1), in the vascular endothelium 
within the inflamed pancreatic islets in NOD mice (Hänninen et al. 1993; Faveeuw 
et al. 1994; Hänninen et al. 1996). The development of insulitis and diabetes can be 
protected by monoclonal antibodies to mucosal addressin cell adhesion molecule-1 
(MAdCAM-1) and to the β7 chain (Yang et al. 1997; Hänninen et al. 1998), 
suggesting that in NOD mice the pathogenesis of diabetes involves the adhesion 
molecules needed for the migration of lymphocytes into the mucosal lymphoid 
tissues. Recently, Turley et al. (2005) showed in mice that intraperitoneally injected 
splenocytes and particulate antigen accumulate in the pancreatic lymph nodes 
suggesting that antigens and immune cells escaping from the gut can easily reach 
27
this site. The transverse colon was also shown to drain through the pancreatic lymph 
nodes (Carter and Collins 1974). Through this routing, immunological activation in 
the gut may modify the presentation of pancreatic self-antigens in the pancreatic 
lymph nodes as well. 
In human studies, as already mentioned, peripheral blood mononuclear cells 
(PBMCs) of patients with T1D show increased humoral and cellular immune 
responses to several dietary proteins from cow’s milk (Savilahti et al. 1988; 
Dahlquist et al. 1992; Cavallo et al. 1996; Saukkonen et al. 1996; Vaarala et al. 
1996) and from wheat (Catassi et al. 1987; Klemetti et al. 1998; MacFarlane et al. 
2003). The densities of T-cells in the intraepithelium and CD25-positive cells in the 
lamina propria are increased in response to gliadin, a solvent-extracted protein of 
gluten, in in vitro cultures of small intestinal biopsies from patients with T1D 
(Auricchio et al. 2004). Auricchio et al. (2004) also showed changes in 
intraepithelial T-cell and lamina propria CD25-positive mononuclear cell densities 
in patients with T1D with no stimulation. Sblattero et al. (2006) were able to isolate 
a lymphocyte clone recognizing a celiac disease-associated antigen from a small 
intestinal biopsy of a patient with T1D and with no signs of celiac disease. The 
PBMCs of this patient did not recognize the same celiac disease -specific antigen. 
In patients with T1D a remarkable proportion of the PBMCs proliferating in 
response to GAD expresses the gut-homing receptor α4β7-integrin (Paronen et al. 
1997), suggesting that the autoantigen-reactive lymphocytes originate from the gut. 
Increased intestinal permeability and ultrastructural changes in microvilli also 
appear to be associated with T1D (Carratù et al. 1999; Secondulfo et al. 2004), 
which may at least partly explain the increased immune response to dietary proteins 
in patients with T1D. Recently it was shown that increased levels of serum zonulin 
were associated with increased intestinal permeability in a subgroup of patients with 
T1D (Sapone et al. 2006). Zonulin is a protein that regulates intercellular tight 
junctions, thus playing a role in intestinal permeability, and whose levels are up-
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regulated in the gut of Bio-Breeding rats (Watts et al. 2005). Furthermore, T1D-
associated increase in the expression of HLA, IL-4, IL-1α, and matrix 
metalloproteinases -1, -3, and -12 by immunohistochemical staining and/or at the 
messenger RNA (mRNA) level was found in small intestinal biopsies showing 
derangements in the gut in patients with T1D (Savilahti et al. 1999; Westerholm-
Ormio et al. 2003; Bister et al. 2005). 
2.6 Insulin as an autoantigen in type 1 diabetes 
2.6.1 Humoral immune response to insulin 
Insulin is one of the major autoantigens of T1D and has some unique features 
compared with other autoantigens. Insulin is the major product of pancreatic islet β-
cells, which are the specific target of autoimmune destruction. Insulin is the only 
T1D-associated autoantigen that is exclusively expressed in the β-cells, with the 
exception of self-antigen -expressing cells in lymphoid tissues such as the thymus, 
where insulin is expressed at low levels without hormonal importance (Pugliese et 
al. 2001). The other autoantigens are expressed in other islet cells and in other 
tissues in addition to the β-cells. Insulin is secreted into the bloodstream and is a 
ubiquitous antigen in this sense. 
In NOD mice over 50% of the T-cell lines obtained from infiltrated islets recognize 
insulin (Wegmann et al. 1994) and these insulin-specific T-cells can transfer the 
disease to the recipient mouse (Daniel et al. 1995). In an international workshop on 
animal models of T1D, it was reported that IAAs are a marker of autoimmunity in 
NOD mice but the other autoantibody assays, GADAs and IA-2As, are questionable as 
markers (Bonifacio et al. 2001). It was also shown that if both native forms of insulin 
are knocked out from NOD mice and compensated for with a mutated form of insulin, 
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that is not a target of autoreactive cells, the disease is avoided (Nakayama et al. 2005). 
These studies suggest that insulin is the primary autoantigen in NOD mice. 
In humans insulin was the first autoantigen identified to which autoantibodies were 
proven to exist (Palmer et al. 1983). In birth-cohort studies, IAAs are quite often the 
first autoantibodies to appear, especially in children who show signs of autoimmunity 
at a young age (Ziegler et al. 1999; Yu et al. 2000; Kimpimäki et al. 2001b). The age 
at onset of clinical T1D correlates inversely with IAA titers (Arslanian et al. 1985; 
Vardi et al. 1988). In addition, the IAA level sometimes fluctuates during the follow-
up: after appearance the IAA level usually rises and later declines, which does not 
commonly occur in other autoantibodies (Ziegler et al. 1999). Further support for the 
essential role of insulin in the pathogenesis of T1D was published recently by Kent et 
al. (2005), who showed that T-cell clones isolated from lymph nodes near the 
pancreatic islets of patients with T1D recognize a particular insulin epitope (A-chain 
amino acids 1-15). This was the first study in which it was possible to culture T-cells 
from the target tissue lymph node instead of PBMCs. 
In addition to IAAs to endogenous insulin, insulin treatment in patients induces 
antibodies to exogenous insulin (Berson et al. 1956). IAAs are used as a marker for 
T1D and insulin antibodies should be distinguished from these. Insulin from different 
animal species induces insulin antibodies in humans differently and bovine insulin is 
more immunogenic than for example porcine or human insulin (Kurtz et al. 1980; 
Reeves and Kelly 1982; Schernthaner 1993). Bovine insulin differs from human 
insulin by only three amino acids and was used for treatment before the availability of 
recombinant human insulin. However, exogenous recombinant human insulin also 
induces insulin antibodies (Fineberg et al. 1983; Schernthaner et al. 1983). 
Both IAAs and insulin antibodies are polyclonal and express a range of fine 
specificities (Potter and Wilkin 2000). IAAs are one of the four autoantibody assays 
commonly used as a marker for autoimmune destruction, but IAAs also include non-
T1D-related specificities. IAAs have been measured with both the liquid-phase 
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radiobinding assay and solid-phase enzyme-linked immunosorbent assay (ELISA), 
of which the radiobinding assay is more useful in detecting T1D-associated 
autoantibodies (Bingley et al. 2003; Bingley and Williams 2004). A microassay 
(radiobinding assay) is widely used for detecting IAAs (Williams et al. 1997) and its 
disease specificity is rather good. But the IAA assay has poor sensitivity among the 
four autoantibody assays: in the Diabetes Antibody Standardization Program the 
sensitivity of the IAA assay in 23 laboratories ranged from 13-66% (Bingley et al. 
2003). Attemps were made to improve the specificity of the IAA assay by measuring 
the affinity of IAAs in competitive assay: children who are at high risk for T1D have 
high-affinity IAAs (Schlosser et al. 2005). Another way to improve the IAA assay 
could be use of the T1D-specific epitope of insulin in the radiobinding assay, but the 
finding of such an epitope has proven difficult. 
2.6.2 Insulin-specific T-cell response 
As already mentioned in chapter 2.3.2, T1D is a T-cell-mediated disease. T-cells can 
be divided into Th cells that express the CD4 receptor, and into cytotoxic T-cells 
that express CD8. Th cells are further classified based on their cytokine secretion: 
Th1 cells secrete high levels of interferon (IFN)-Ȗ and IL-2 and provide help for 
cytotoxic immune responses, and Th2 cells secrete more IL-4, IL-13, and IL-5 and 
help the humoral immune response (Seder and Paul 1994; Mosmann and Sad 1996). 
Typically, the Th1 type of cytokine environment down-regulates the Th2 response 
and vice versa. T1D is considered to be Th1-mediated at the level of the target 
organ, where CD8 cells are believed to mediate ȕ-cell destruction. 
Recently, a novel Th cell lineage was characterized: Th17 cells (Weaver et al. 2006). 
The development of Th17 cells differs from that of effector Th1 and Th2 cells and 
from regulatory T-cells. Th17 cells produce IL-17 and IL-6 and their development is 
dependent on the presence of transforming growth factor (TGF)-ȕ.
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In addition to Th1, Th2 and Th17 cells there are different types of regulatory T-cells 
circulating in the periphery. Thymus-derived, self-antigen-recognizing 
CD4+CD25high regulatory T-cells express specifically Foxp3 transcription factor, 
which probably plays an essential role in the development and function of regulatory 
T-cells (Fontenot et al. 2003; Khattri et al. 2003; Yagi et al. 2004). These regulatory 
T-cells also constantly express CTLA-4 and glucocorticoid-inducible tumor necrosis 
factor receptor (GITR). These CD4+CD25high regulatory T-cells express at least the 
membrane-bound form of TGF-β (reviewed by Fontenot and Rudensky 2005; 
Sakaguchi 2005). In humans Foxp3-expressing CD4+CD25high regulatory T-cells 
can be induced from peripheral CD4+CD25- cells on stimulation (Walker et al. 
2003; Rao et al. 2005). In addition to these CD4+CD25high regulatory T-cells, there 
are Th3 and Tr1 types of cells that are able to suppress T-cell responses in the 
periphery (Cottrez and Groux 2004). Th3 cells are characterized by their secretion of 
IL-4 and TGF-β and Tr1 cells by their secretion of IL-10. Peripherally induced 
regulatory cells are distinct from the thymus-derived CD4+CD25highFoxp3+ 
regulatory T-cells in their specificity to foreign exogenous antigens. 
Although T1D is considered as a T-cell mediated disease, the only methods available 
for measuring possible β-cell damage are based on autoantibodies. There are as yet no 
generalized widespread autoantigen-specific T-cell assays used for the prediction of 
T1D as the autoantibody assays. Insulin-specific autoreactive T-cells in patients with 
T1D and at risk for T1D have been studied since 1975 (MacCuish et al. 1975). 
MacCuish et al. used the T-cell proliferation test and found differences between the 
patients and unaffected subjects, although not all unaffected subjects were negative 
and the stimulation indices were usually low. It was recently proposed that patients 
with T1D and unaffected subjects differ in the quality of their T-cell responses to islet 
autoantigens: the patients show polarization to the Th1 phenotype by secreting IFN-Ȗ
and healthy subjects show regulatory T-cell phenotype by secreting both IFN-Ȗ and 
IL-10 in response to islet-derived peptides (Arif et al. 2004). 
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Animal insulins used as treatment also result in higher T-cell proliferation responses 
to exogenous insulin than human insulin in a manner similar to that of insulin 
antibodies (Naquet et al. 1988). However, the humoral immune response to insulin 
and T-cell response to insulin usually do not correlate (Kurtz et al. 1985; Keller 
1990; Mayer et al. 1999). An inverse correlation was also reported (Schloot et al. 
1997; Dubois-LaForgue et al. 1999). 
In addition to T-cell proliferation tests, several T-cell methods have been tested in 
the study of insulin-reactive T-cells in peripheral blood. Insulin-specific T-cell lines 
and a T-cell clone were cultured from PBMCs of patients with T1D (Miller et al. 
1987; Schloot et al. 1998; Semana et al. 1999; Alleva et al. 2001). One study group 
examined the cellular responses to bovine and porcine insulin using a cytotoxicity 
assay (Richens et al. 1986). An enzyme-linked immunospot (ELISPOT) assay was 
one of the methods used in attempts to compensate for the difficulties in 
autoantigen-specific T-cell assays associated with T1D and several studies of 
insulin- or insulin-peptide-specific enzyme-linked immunospot (ELISPOT) assays 
were published (Karlsson et al. 2000; Alleva et al. 2001; Arif et al. 2004). One of the 
novel methods used to find rare insulin-specific T-cells among PBMCs is to make 
insulin-peptide HLA-tetramers and detect tetramer binding to T-cells by means of 
flow cytometry (Öling et al. 2005). 
However, in most of these insulin-specific T-cell assays the response is not T1D-
specific since the unaffected controls also show cellular responses to insulin. Maybe 
one of the major problems is that the T-cell assays can use only PBMCs and there is 
no access to the target tissue of T1D. Usually the frequency of antigen-specific T-
cells in the circulation is between 1:10 000 and 1:1 000 000 and most likely the 
proportion of autoantigen-specific T-cells is extremely low. In addition, finding the 
appropriate form of insulin (from which species, whole insulin or A- and B-chain or 
proinsulin, in which concentration, etc.) or even the T1D-associated epitope of 
insulin has been difficult and not yet accomplished. 
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3 AIMS OF THE STUDY 
The aim was to characterize the insulin-specific immune responses in children 
newly diagnosed with T1D both before and after initiating insulin treatment, to 
measure the insulin-specific immune response in relation to mother’s breast milk 
insulin content in suckling infants at risk for T1D, and to characterize the 
immunological changes in the small intestine of patients with T1D. The detailed aim 
of each publication was as follows: 
I   The aim of the first publication was to determine whether the formation of 
insulin-insulin antibody immune complexes could be the reason for the fluctuations 
in serum IAA levels and poor sensitivity of IAAs. 
II  In the second publication the effect of insulin treatment on the cellular immune 
response to insulin was detected both at the effector T-cell and regulatory T-cell levels. 
III  Since dietary bovine insulin in cow’s milk induces immune responses to insulin in 
small infants, we studied whether a high insulin concentration in mother’s breast milk 
would correlate with reduced humoral insulin-specific immune responses in the infant. 
IV  In the fourth publication the aim was to characterize the immunological changes 
in small intestinal biopsies of patients with T1D by screening for common markers 
of inflammation, effector and regulatory T-cell markers, and markers produced by 
antigen-presenting cells. 
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4 SUBJECTS AND METHODS 
4.1 Subjects
Publication I 
Plasma samples derived from Ficoll-Paque density gradient centrifugation were used 
in the study. The study included 23 patients with recently diagnosed T1D from the 
Hospital for Children and Adolescents, Helsinki and from the Jorvi Hospital, Espoo, 
Finland. The study protocol was approved by the ethics committees of the 
participating hospitals. A total of 21 of the patients were studied within 10 days after 
the diagnosis of T1D and two patients 3 weeks after the diagnosis. 
In all, 17 patients diagnosed within 10 days after the diagnosis showed negative IAA 
levels in the plasma and their mean age was 8.5 years (range 1.6 - 12.9 years). Of 
these newly diagnosed children, 14 tested negative for plasma GADAs and their 
mean age was 7.7 years (range 0.8 - 13.5 years). 
The study included 23 unaffected children without acute infections or autoimmune 
diseases from the Hospital for Children and Adolescents. All these control children 
were negative for IAAs and their mean age was 7.3 years (range 1.6 - 14.7 years). 21 
of the control children tested negative for GADAs and the mean age of this 
subgroup of unaffected children was 7.1 years (range 1.6 - 14.7 years). 
Publication II 
The PBMC samples for the reverse transcriptase-polymerase chain reaction (RT-
PCR), for cytometric bead array (CBA) measurements, and for T-cell proliferation 
tests were taken from 33 newly diagnosed patients with T1D. The blood sample 
from 12 of these patients was taken at diagnosis before starting exogenous insulin 
therapy and the mean age in this group 0 was 7.1 years (range 1.9 - 12.5 years). In 
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all, 21 patients had been treated with insulin for 1-21 days at the time of sampling 
and this group 1 had a mean age of 7.7 years (range 1.8 - 14.4 years). Ten unaffected 
children undergoing minor surgery at the Hospital for Children and Adolescents 
were studied as controls and their mean age was 6.5 years (range 1.2 - 15.8 years). 
The PBMC samples for flow cytometry included 12 children with newly diagnosed 
T1D and four unaffected controls. Seven patients were in group 0, before insulin 
treatment, and the mean age was 6.5 years (range 1.1 - 12.8 years). Five patients were 
treated with insulin (group 1) and their mean age was 7.5 years (range 3.6- 13.2 years). 
The four control children had a mean age of 7.1 years (range 3.5 - 10.1 years). 
All the patient samples were from the Hospital for Children and Adolescents, 
Helsinki and from the Jorvi Hospital, Espoo, Finland. The ethics committees of the 
hospitals had given approvals for the study. 
Publication III 
This study included a subgroup of 128 children participating in the TRIGR pilot 
study. In the TRIGR intervention trial all the children had T1D-associated HLA risk 
alleles (HLA-DQB1*0302 and/or DQB1*0201) without protective alleles 
(DQB1*0301, *0602, *0603) and had a first-degree relative with T1D (mother, 
father, or a sibling). The children were randomized into two groups: after exclusive 
breast-feeding, the children received either study formula based on hydrolyzed 
casein (Nutramigen™, Mead Johnson, Evansville, IL, USA) or a regular cow’s 
milk-based infant formula (Enfamil™, Mead Johnson) comprising 80% Enfamil™ 
and 20% Nutramigen™ during the first 6-8 months of life. The children avoided all 
cow’s milk or cow’s meat-containing food during the intervention period until 6-8 
months of age. The children were invited to give a blood sample at 3, 6, 9, 12, 24, 
36, 48, and 60 months of age during a mean observation period of 4.7 years and the 
occurrences of ICAs, IAAs, GADAs, and IA-2As were screened (detailed 
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description of TRIGR pilot study by Åkerblom et al. 2005). Insulin antibodies were 
measured from the 3-, 6-, 9-, and 12-month plasma samples. From the mothers of 
TRIGR children in this study breast milk samples were collected at 3-7 days and/or 
3 months after delivery (95 samples at 3-7 days and 106 at 3 months). 
Publication IV 
Small intestinal biopsies from the distal duodenum were obtained from 65 pediatric 
patients at the Hospital for Children and Adolescents, Helsinki, Finland. The 
patients were divided into six groups covering two diseases: T1D and celiac disease. 
Of these patients, 29 children had T1D and were divided into three groups: 12 
patients with active celiac disease at the time of sampling (mean age 7.7 years, range 
3.3 - 14.3 years), eight T1D patients with normal villous structure but elevated 
density of intraepithelial lymphocytes (IELs) and/or presence of celiac disease-
associated autoantibodies indicating potential celiac disease (mean age 8.1 years, 
range 4.5 - 15.0 years), and nine patients with normal villous structure and normal 
density of IELs (mean age 10.6 years, range 3.5 - 18.2 years). The small intestinal 
biopsy was taken due to positive findings in the annual celiac disease screening test, 
including immunoglobulin (Ig)A and IgG gliadin, IgA endomysium and tissue-
transglutaminase antibodies, or to gastrointestinal symptoms. 
In addition to children with T1D, 15 patients with active, untreated celiac disease were 
studied (mean age 7.0 years, range 1.2 - 12.6 years) and seven children with increased 
density of IELs and/or celiac disease-associated antibodies indicating potential celiac 
disease (mean age 8.9 years, range 4.0 - 15.2 years). Furthermore, 14 age-matched 
children without autoimmune diseases were studied as a control group (mean age 6.2 
years, range 1.1 - 14.1 years). The biopsies were taken for growth retardation, 
gastrointestinal symptoms, positive anti-gliadin antibodies, or any combination of 
these. The morphology of the jejunum was normal and the endomysium and tissue 
transglutaminase antibodies were negative in all control children. 
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The use of biopsy specimens for the study was approved by the ethics committee of 
the Hospital for Children and Adolescents. Written consent was signed by the 
parents of the children. 
4.2 Methods
Table 1 presents which procedures and methods were used in each publication. The 
methods are explained shortly in this chapter but the detailed descriptions are printed 
or referred to in the original publications. All the antibodies used are listed in Table 2. 
Separation of IgG fraction 
IgG was isolated from plasma, using protein A affinity column (Pharmacia Biotech, 
Uppsala, Sweden). The IgG fraction was eluted from the column with citric acid pH 
3.9, neutralized, and concentrated with an ultrafiltration cell using a membrane with 
a molecular weight cutoff of 10 000 D. The total concentration of IgG was 
measured from the IgG fractions and the corresponding plasmas with an automated 
clinical chemistry analyzer. Both the IgG fraction and the corresponding plasma 
were diluted to the same IgG concentration which corresponded to the concentration 
of the plasma diluted 1:2. 
IAAs, GADAs, IA-2As, and ICAs 
The autoantibodies associated with T1D were measured in the laboratory of 
Professor Mikael Knip. The methods are referred to in the original publications. 
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Table 1. Procedures and methods 
Procedure Method Publication Reference 
Separation of IgG fraction Protein A affinity 
chromatography 
I I 
Insulin autoantibodies (IAAs) Radioimmunoassay I, II, III Ronkainen 
et al. 2001 
GAD autoantibodies 
(GADAs) 
Radioimmunoassay I, III Kulmala et 
al. 1998 
Stimulation of PBMCs Cell culturing II II 
Quantitative measurement of 
mRNAs 
Quantitative RT-
PCR
II, IV II, IV 
Detection of secreted 
cytokines
Cytometric bead 
array (CBA) kit 
II *Becton 
Dickinson 
Detection of Foxp3+ PBMCs Flow cytometry II Roncador et 
al. 2005 
Detection of antigen-specific 
T-cells
T-cell proliferation 
test
II II 
Insulin antibodies ELISA III Vaarala et  
al. 1999 
Measuring insulin 
concentration 
ELISA kit III *DRG 
Diagnostics
Detection of Foxp3+ and 
CD25+ cells in gut biopsies 
Immunohisto-
chemistry 
IV IV 
* According to the manufacturer’s instructions 
PBMC culture 
PBMCs were isolated from heparinized blood with Ficoll-Paque density gradient 
centrifugation and cultured for 72 hours in U-bottomed 96-well cell culture plates at 
2 x 105 cells per well in triplicate wells with or without antigens. Tetanus toxoid 20 
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ȝg/ml, bovine insulin 300 ȝg/ml, and human insulin 300 ȝg/ml were used as 
antigens. The supernatants were collected for the detection of secreted cytokines, 
using a CBA, and the cells were collected for the study of mRNA expressions, using 
quantitative RT-PCR. 
Quantitative RT-PCR 
Total RNA was extracted from the samples with a commercial kit (GenElute 
Mammalian Total RNA Miniprep kit, Sigma, St. Louis, MO, USA) and reverse 
transcription reaction was performed. A quantitative RT-PCR was carried out with 
commercial primers and probes, using an ABI-Prism 7700 Sequence Detection 
System (Applied Biosystems, Foster City, CA, USA) in triplicate wells. 18S RNA 
was used as an endogenous control. PBMCs phytohemagglutinin-stimulated for 48 
hours were used as a calibrator sample that was included in every plate. The 
quantities of the markers were analyzed with a comparative threshold cycle (CT)
method and were presented as relative amounts (2-ΔΔCt): ΔCT is calculated by 
subtracting the CT value of the 18S gene from the CT value of the marker gene, 
whereas ΔΔCT is the difference between the ΔCT of the analyzed sample and the 
ΔCT of the calibrator. Calculation of 2-ΔΔCt then gives a relative amount of the 
analyzed sample compared with the calibrator. 
Cytometric bead array (CBA) 
Secreted IFN-γ, IL-5, IL-4, IL-2, and IL-10 were measured with a flow cytometry-
based CBA kit (BD Pharmingen, San Diego, CA, USA). The kit is based on the use 
of beads that are coated with capture antibodies for the cytokines and the beads for 
each cytokine are distinguished from each other by different intensities of a 
fluorescence label. After the beads are incubated with the sample supernatants and 
the cytokines allowed to attach to the antibodies, a detection antibody labeled with 
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another fluorescence label is added to form a sandwich complex around the 
cytokine. The intensity of the fluorescence from the capture antibody is proportional 
to the concentration of the cytokine in the sample. 
Table 2. Antibodies used in the detection of IgG concentration (I), flow cytometry (II), insulin 
antibody ELISA (III), and immunohistochemical stainings (IV). 
Antibodies Conjugate Source (clone) Publication 
rabbit anti-human IgG - Dako I 
mouse anti-human Foxp3 - 
Gift from A.H. 
Banham,UK (150D/E4) 
II
goat anti-mouse IgG Alexa 488 Molecular Probes II 
mouse anti-human CD4 PerCP Becton Dickinson II 
mouse anti-human CD25 PE Miltenyi Biotech II 
rabbit anti-human IgG 
Alkaline 
phosphatase 
Jackson
ImmunoResearch 
III
mouse anti-human Foxp3 - Abcam (236A/E7) IV 
mouse anti-human CD25 - Dako (ACT-1) IV 
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Detection of Foxp3 by flow cytometry 
Ficoll-Paque-isolated PBMCs were cultured with or without antigens for 5-6 days in 
a 24-well cell culture plate at 2 x 106 cells per well before staining for flow 
cytometry. The Foxp3 staining was adapted from a paper by Roncador et al. (2005). 
The cells were fixed, permeabilized, and treated with DNAse, since Foxp3 is a 
nuclear protein. The cells were blocked with goat IgG before staining with unlabeled 
mouse anti-human Foxp3 antibody and Alexa fluor 488-labeled goat anti-mouse IgG 
was used as a secondary antibody. The cells were still blocked with mouse IgG 
before staining with labeled mouse anti-human CD4-PerCP and CD25-PE 
antibodies. The cells were analyzed with FACSCalibur and CellQuest Pro software 
(Becton Dickinson, San Jose, CA, USA). 
T-cell proliferation test 
PBMCs isolated with Ficoll-Paque density gradient centrifugation were cultured in 
U-bottomed 96-well cell culture plates at 1 x 105 cells per well in quadruplicate 
wells with or without antigen. After incubation for 5 days, 1 ȝCi of tritiated 
thymidine was added to each well and the cells were harvested 16 - 18 h later to 
measure the incorporation of radioactivity. Stimulation indices were calculated by 
dividing the median counts per minute measured from the antigen-stimulated wells 
by the median counts per minute detected in the wells cultured without antigen.  
Insulin antibody ELISA 
Insulin-specific antibodies in plasma were measured with a homemade ELISA 
coated with bovine or human insulin. Human serum albumin was used for residual 
coating. Alkaline-phosphatase-conjugated rabbit anti-human IgG was used as a 
secondary antibody. 
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Procedure to measure insulin concentration 
Breast milk samples were centrifuged at 10 000 x g for 30 minutes before measuring 
the insulin concentration. After centrifugation both cellular debris and the fat layer 
on the top were discarded. The clear middle layer was used for the analyses. A 
commercially available ELISA kit was used for the determination of insulin 
concentration (DRG Diagnostics, Germany).
Immunohistochemistry
Paraffin sections of small intestinal biopsies were used for immunohistochemical 
staining of Foxp3 and CD25. The slides were first deparaffinized and antigen 
retrieval was performed using microwave cooking in citrate buffer (pH 6.0) for 
Foxp3 and in 2mM ethylenediaminetetraacetic acid and 50 mM Tris (pH 9.0) for 
CD25. Endogenous peroxidase activity was quenched with 0.5% H2O2 in methanol. 
The slides were blocked with horse serum before staining with primary monoclonal 
mouse anti-human antibodies. The bound antibodies were detected with an avidin-
biotin immunoperoxidase kit (Vectastain Elite ABC Kit, Vector Laboratories, 
Burlingame, CA, USA) and counterstained with hematoxylin. The calculated cell 
densities were expressed as the mean number of positively stained cells/mm2 in the 
lamina propria. 
Statistical analyses 
The non-parametric Kruskal-Wallis test and Mann-Whitney U-test were used for 
comparisons between the study groups. The spearman rank correlation test was used 
to analyze correlations between different parameters. Two-tailed p-values < 0.05 
were considered significant (SPSS 10.0 for Windows, SPSS Inc, Chicago, IL, USA). 
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5 RESULTS
5.1 Insulin autoantibody levels in IgG fractions of children with 
recent-onset type 1 diabetes and negative for plasma insulin 
autoantibodies (I) 
IgG was isolated from the plasma samples of 17 newly diagnosed patients with T1D 
and of 23 unaffected children who were all negative for plasma IAAs. The IgG 
concentrations of the IgG fractions and plasmas were measured and the total IgG 
concentrations did not differ between patients and unaffected controls. Table 3 
shows the IgG concentrations in the plasma samples and the IAA levels in the IgG 
fractions and corresponding plasma samples. 
The IAA levels of the IgG fractions were higher in the patients with newly 
diagnosed T1D than in the control children (p=0.004). (Figure 1.) The cutoff limit of 
the IAA assay used in this study was 1.55 RU (relative unit). In the IgG fractions 
this value was exceeded in 8 out of 17 patients (47%), who were negative for plasma 
IAAs, and in 3 out of 23 (13%) unaffected children. 
Figure 1. Levels of IAAs in IgG fractions in children negative for plasma IAAs. Median values of 
patients with recent-onset T1D and control children are shown as horizontal lines. 
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Table 3. IgG concentrations in plasma (mg/ml) and results of IAAs (RU, relative unit) in plasma 
samples and in corresponding IgG fractions in children with recent-onset T1D and in unaffected 
children. The cutoff limit for IAA positivity was 1.55 RU and values exceeding this are bolded. 
Diabetic patients Control children 
IgG
conc.
IAA / 
plasma 
IAA / IgG 
fraction 
IgG
conc.
IAA / 
plasma 
IAA / IgG 
fraction 
5.00 1.23 22.35 10.70 1.00 1.00 
6.74 1.00 2.93 8.90 1.00 1.00 
9.20 1.00 1.00 10.96 1.00 1.68 
6.06 1.12 1.46 6.16 1.00 1.00 
6.52 1.00 1.00 11.54 1.00 1.00 
9.18 1.00 1.00 5.80 1.00 5.58 
9.04 1.00 1.46 9.32 1.00 6.03 
8.26 1.00 1.00 7.84 1.00 1.00 
9.40 1.00 4.50 6.80 1.00 1.00 
3.14 1.00 1.00 6.16 1.00 1.00 
7.94 1.00 7.29 9.26 1.00 1.00 
6.60 1.00 3.02 8.78 1.00 1.00 
9.16 1.00 5.90 7.78 1.00 1.00 
5.82 1.00 3.31 6.62 1.00 1.00 
6.52 1.00 5.16 8.52 1.00 1.00 
7.30 1.00 1.00 7.94 1.00 1.00 
6.94 1.00 1.00 8.14 1.00 1.00 
   7.94 1.00 1.00 
   8.56 1.00 1.00 
   8.90 1.00 1.00 
   5.84 1.00 1.00 
   9.54 1.00 1.00 
   7.86 1.00 1.00 
GADAs were also measured from the plasma samples and the IgG fractions. The 
levels of GADAs tended to be higher in the IgG fractions than in the corresponding 
plasma samples, but the GADAs measured in the IgG fractions did not differ 
between the patients and the unaffected controls negative for plasma GADAs. 
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5.2 Insulin-induced in vitro up-regulation of regulatory T-cell 
markers in peripheral blood mononuclear cells (II) 
PBMCs were obtained from both insulin-treated (group 1) and untreated (group 0) 
patients with newly diagnosed T1D and from unaffected children. The PBMCs were 
cultured for 72 hours with bovine or human insulin (or with tetanus toxoid as a 
control antigen) before detecting the expression of regulatory T-cell markers Foxp3, 
CTLA-4, and inducible co-stimulator (ICOS), and cytokines TGF-β, IFN-γ, IL-4, 
and IL-5 at the mRNA level. The secretion of IFN-γ, IL-4, IL-5, IL-2, and IL-10 was 
measured with a CBA kit. 
Both bovine and human insulin induced higher expression of the regulatory T-cell 
markers Foxp3 (p=0.040 and p=0.055 for bovine and human insulin, respectively), 
CTLA-4 (p=0.035 and p=0.009), and ICOS (p=0.025 and p=0.018) at the mRNA 
level in patients with T1D treated with insulin compared with patients with T1D 
studied before initiating insulin therapy. (Figure 2.) Bovine insulin also induced 
higher Foxp3 (p=0.002, median relative amounts were 10.6 and 4.0), CTLA-4 
(p=0.002, medians 8.1 and 0.2) and ICOS (p=0.005, medians 9.1 and 5.0) mRNA 
levels in patients on insulin treatment compared with unaffected children. 
The bovine and human insulin-induced expression levels of Foxp3, CTLA-4, and 
ICOS mRNAs correlated with each other (r=0.44, p=0.011; r=0.42, p=0.016; r=0.45, 
p=0.017; respectively). Bovine insulin-induced Foxp3 mRNA expression correlated 
with bovine insulin-induced CTLA-4 and ICOS mRNA expressions (r=0.78, 
p<0.001 for CTLA-4; r=0.69, p<0.001 for ICOS), while human insulin-induced 
Foxp3 mRNA correlated with human insulin-induced CTLA-4 and ICOS mRNA 
levels (r=0.71, p<0.001 for CTLA-4; r=0.55, p=0.003 for ICOS). The human 
insulin-induced expression of Foxp3 mRNA in insulin-treated patients correlated 
inversely with HbA1c values detected 5-6 months after diagnosis (r=-0.66, 
p=0.038), but bovine insulin-induced Foxp3 mRNA expression was directly 
correlated with the HbA1c values in patients on insulin treatment (r=0.74, p=0.010). 
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Figure 2. Foxp3-, CTLA-4- and ICOS-specific mRNA expression levels after bovine (A, C, E) and 
human insulin (B, D, F) stimulations. Samples from T1D patients in group 0 were taken at the time 
of diagnosis before starting insulin treatment. In group 1 the T1D patients were treated with insulin 
for 1-21 days. Horizontal lines show medians for each group. 
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We next analyzed whether the increase in the mRNA levels of regulatory cell 
markers was due to an increase in the number of regulatory T-cells. The insulin-
induced increase in vitro in the number of regulatory T-cells, CD4+CD25highFoxp3+ 
cells, was confirmed by flow cytometric analysis after culturing PBMCs for 5-6 
days. The proportions of bovine and human insulin-induced CD4+CD25high cells 
among CD4+ cells are presented in Table 4. Approximately half of these 
CD4+CD25high cells expressed Foxp3 (range 42.7%-57.9% after bovine insulin 
stimulation and 52.0-62.5% after human insulin stimulation), as shown in Figure 3. 
Table 4. Proportions of CD4+CD25high cells among CD4+ cells in flow cytometric analysis after 
bovine or human insulin stimulation in patients with newly diagnosed T1D (group 0 refers to 
patients before initiating insulin therapy and group 1 to patients on insulin therapy) and in 
unaffected children. The cells cultured without antigen showed very few CD4+CD25high cells 
among CD4+ cells in all children (median 0.1%, mean 0.3%). This background is subtracted from 
the insulin-induced results. 
Group Subject 
Increase in CD4+CD25high
cells after bovine insulin 
stimulation (%) 
Increase in CD4+CD25high
cells after human insulin 
stimulation (%) 
0 patient 1 1.1 0 
0 patient 2 0.1 0 
0 patient 3 2.1 - 
0 patient 4 4.7 0 
0 patient 5 1.2 0.4 
1 patient 6 6.5 1.0 
1 patient 7 4.2 1.1 
1 patient 8 1.2 0.2 
1 patient 9 9.0 1.7 
control control 1 2.6 0 
control control 2 2.3 0.1 
control control 3 0.8 1.4 
control control 4 2.4 1.7 
    
48
Figure 3. Flow cytometric analysis of CD4+ 
CD25high Foxp3+ cells in a representative 
patient with newly diagnosed T1D. Plot A 
shows how the CD4+CD25high cells are gated 
for plots B and C. Plot B shows bovine 
insulin- and plot C human insulin-induced 
Foxp3 expression. The histograms colored 
with gray represent the staining with anti-
Foxp3 antibody and the uncolored histograms 
represent staining with a control antibody.
 Figure 4. Bovine (A) and human (B) 
insulin-induced expression of IL-4 mRNA 
after 72 hours stimulation of PBMCs. Group 
0 represents patients with T1D at diagnosis 
before initiating exogenous insulin therapy 
and group 1 recent-onset patients after 
treatment with insulin for 1-21 days. 
Medians are marked with horizontal lines.
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The cytokine-specific mRNA expressions did not differ between the T1D patient 
groups (before or after initiating insulin treatment). The IL-4 mRNA expression was 
increased in both patient groups in comparison to unaffected children after bovine 
(p=0.007 for group 0 and p=0.002 for group 1) and human insulin stimulation 
(p=0.033 for group 0 and p=0.057 for group 1). (Figure 4.) Bovine insulin-induced 
secretion of IL-4 was also higher in T1D patients treated with insulin than in the 
control children (p=0.014, median levels were 0.8 and 0 pg/ml). The IFN-Ȗ, IL-5, or 
TGF-β mRNA expressions, as well as the secretion of IFN-Ȗ, IL-5, IL-2, or IL-10, 
did not differ between the study groups after the insulin stimulations. With a T1D-
unrelated antigen, tetanus toxoid, we could find no similar differences between the 
study groups in the expression of regulatory T-cell markers or IL-4. 
In the T-cell proliferation test the study groups did not differ in response to bovine 
or human insulin or tetanus toxoid. The stimulation indices in proliferation after 
bovine insulin stimulation correlated with the quantities of bovine-induced IFN-γ,
IL-5, Foxp3, and CTLA-4 at the mRNA level (r=0.54, p=0.002 for IFN-γ, r=0.62, 
p<0.001 for IL-5, r=0.51, p=0.003 for Foxp3, and r=0.43, p=0.016 for CTLA-4), and 
IFN-γ and IL-5 at the protein level (r=0.61, p=0.001 for IFN-γ and r=0.65, p<0.001 
for IL-5) in the total series. In contrast, the human insulin-induced expression of 
IFN-γ, IL-5, Foxp3, or CTLA-4 did not correlate with the proliferation response 
induced by human insulin. The proliferation response to human insulin correlated 
inversely with the quantity of human insulin-induced TGF-β mRNA (r=-0.41, 
p=0.029) or with IAAs (r=-0.42, p=0.044). The IAA levels correlated with the 
quantities of IL-4 and TGF-β mRNAs in response to human insulin in patients with 
newly diagnosed T1D (r=0.46, p=0.027 for IL-4 and r=0.60, p=0.003 for TGF-β).
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5.3 High concentration of insulin in breast milk is associated with 
decreased humoral immune response to dietary insulin in the 
offspring (III) 
The bovine and human insulin-specific IgG class antibodies were measured with 
ELISA from blood samples taken at 3, 6, 9, and 12 months of age from the TRIGR 
children. The breast milk samples from the mothers of the children at 3-7 days and 3 
months after delivery were analyzed for insulin content. 
The insulin concentrations in breast milk samples varied between 0 and 14 μg/l and 
no differences were found between the samples taken at 3-7 days or 3 months after 
delivery. The concentrations of insulin in breast milk were higher in mothers 
affected with T1D than in nondiabetic mothers in both the 3-7-day samples 
(p=0.007) and in the 3-month samples (p<0.001). (Figure  5.) 
Figure 5. Insulin concentrations in breast milk samples 3-7 days (A) or 3 months (B) after delivery 
in mothers with or without T1D. The median values are shown with horizontal lines.
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The concentration of insulin in breast milk taken 3 months after delivery correlated 
inversely with the bovine insulin-specific antibody levels detected at 6 months of 
age in children exposed to cow’s milk-based formula (r=-0.39, p=0.013). No 
association was seen in children who had received casein hydrolysate formula (r=-
0.08, p=0.610). At 12 months of age, when all the children were exposed to cow’s 
milk in their diet, an inverse correlation was seen between bovine insulin-specific 
antibody levels and the concentrations of insulin in breast milk 3 months after 
delivery in all subjects (r=-0.25, p=0.029). (Figure 6.) 
Figure 6. Correlation between insulin 
concentration in breast milk at 3 months and 
bovine insulin antibodies in plasma at 6 
months (A) or 12 months (B) of age. A): 
infants in cow’s milk formula group and B): 
all children. 
Figure 7. Insulin content in breast milk (at 3 
months) in all mothers (A) and in diabetic 
mothers (B). The groups represent children 
positive (autoab+) or negative (autoab-) for 
T1D-associated autoantibodies. Median 
insulin concentrations are shown. 
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The breast milk insulin concentrations 3 months after delivery were higher in the 
mothers of those children who became positive for T1D-associated autoantibodies 
during the follow-up (p=0.030). The same finding held when only children of 
mothers with T1D were included in the analysis (p=0.045). (Figure 7.) 
5.4 Increased IL-18 mRNA expression in the small intestine of 
children with type 1 diabetes (IV) 
The expression of several immunological markers at the mRNA level was studied in 
duodenal biopsies of children with T1D and active celiac disease, T1D and potential 
celiac disease, T1D and normal intestinal mucosae, active celiac disease, potential 
celiac disease, and control children with normal intestinal mucosae. IL-8 and IL-6 
were studied as common markers of inflammation, IL-18 and IL-15 as cytokines 
expressed by antigen-presenting cells, IFN-γ as a marker for Th1 immune responses, 
IL-4 as a marker for Th2 immune responses, and Foxp3, TGF-β, and IL-10 as 
markers for regulatory T-cells. CD25 expression, which is associated with both 
activated effector T-cells and regulatory T-cells, was also studied. 
The expression of IL-18-, Foxp3-, IL-10-, IFN-γ-, and CD25-specific mRNAs differed 
between the six study groups (in the Kruskal-Wallis test p<0.001 for IL-18, IL-10 and 
IFN-γ; p=0.008 for Foxp3 and p=0.023 for CD25). Those children with T1D with no 
signs of celiac disease or potential celiac disease expressed higher levels of IL-18 
mRNA in small intestinal biopsies than control children with normal mucosae 
(p=0.035). Pediatric patients with T1D also differed from children with celiac disease, 
T1D and celiac disease, and potential celiac disease (all p-values were <0.001). In 
addition, children with T1D and potential celiac disease expressed higher levels of IL-
18 mRNA than patients with celiac disease, T1D and celiac disease, and potential 
celiac disease (all p-values were < 0.001). In patients with active or potential celiac 
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disease the expression of IL-18 mRNA was lower than in control children with normal 
mucosae (p=0.004 and p=0.025 respectively). (Figure 8.) 
Figure 8. Expression of IL-18-specific mRNA in small intestinal biopsies measured by 
quantitative RT-PCR. The horizontal lines show medians for each group. CD = celiac disease, 
potCD = potential celiac disease with elevated levels of TCR γ/δ -expressing IELs and/or presence 
of celiac disease-associated antibodies, CONTR = control group with normal mucosae. 
Pediatric patients with T1D did not differ from the control group in the expression of 
any other marker tested. The increased expression of Foxp3, IL-10, IFN-γ, and 
CD25 was associated with celiac disease. The expression of these markers at the 
mRNA level was confirmed at the protein level by immunohistochemistry only with 
Foxp3 and CD25, the staining of which correlated with the RT-PCR results. 
Immunohistochemical staining of cytokines in the paraffin sections was not done. 
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6 DISCUSSION 
6.1 Insulin autoantibodies can be detected in isolated IgG fractions 
of children with type 1 diabetes and negative for plasma 
insulin autoantibodies (I) 
This study showed that about half of the patients with T1D tested positive for IAAs, 
when the IAA assay was performed in the isolated IgG fraction instead of plasma in 
subjects whose plasma tested negative for IAAs. Overall the levels of 
autoantibodies, both IAAs and GADAs, were increased after IgG fractionation in 
comparison to plasma. But only with IAAs did the levels detected in patients with 
T1D exceed significantly the levels detected in the unaffected children. 
This finding suggests that insulin may circulate in plasma as insulin-IAA immune 
complexes that are not detectable in micro-IAA assay. The IgG fraction was eluted 
with acidic buffer which allows the immune complexes to dissociate, while dialysis 
during the concentration of the IgG fraction permits a small molecule such as insulin 
to be discarded. Another possibility is that some unknown molecule in plasma may 
interfere with the IAA assay and this molecule may be discarded during the 
fractionation of IgG. However, this phenomenon appears to affect especially IAA 
assay with poor sensitivity, but not the GADA assay. 
The isolation of the IgG fraction in this study is a laborious method that is not 
suitable for large-scale screening, and thus does not as such offer an improvement in 
IAA methodology. Furthermore, IgG fractionation may decrease the specificity of 
the IAA assay, since 3 out of 23 control children became positive for IAAs after 
isolation of the IgG fraction. However if the IgG fractions were used for measuring 
IAAs, a new cutoff limit for positivity in the assay should be assessed with a 
sufficient number of IgG fractions from unaffected children. In conclusion, this 
finding that the IAA assay performed in plasma or serum samples may result in a 
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significant proportion of false-negative results may at least partly explain the 
fluctuation of IAA levels seen in follow-up studies. 
6.2 Insulin treatment stimulates regulatory T-cells in patients with 
newly diagnosed type 1 diabetes (II) 
In vitro human and bovine insulin stimulation of PBMCs resulted in an increased 
expression of the regulatory T-cell markers Foxp3, CTLA-4, and ICOS in those T1D 
patients who had been treated with exogenous insulin. The PBMCs of children at 
diagnosis of T1D before receiving insulin therapy showed no increment of 
regulatory T-cell markers after insulin stimulation. The mRNA expression levels of 
all three regulatory T-cell markers correlated with each other which confirms the 
finding. The phenomenon could likewise not be seen with the T1D-unrelated 
antigen, tetanus toxoid. This finding suggests that exogenous insulin treatment 
affects the population of regulatory T-cells in vivo. In animal studies it was shown 
that peripheral autoantigen can induce activation of regulatory T-cells (Seddon and 
Mason 1999; Masteller et al. 2005). 
We also showed at the protein level, using flow cytometry, that in vitro human and 
bovine insulin stimulation increases the proportion of CD4+CD25highFoxp3+ cells. 
However, the same increase was also seen in unaffected children and the number of 
patients studied was too small to speculate if the increment was higher in those 
patients on insulin treatment compared with the untreated patients. 
In the animal model of T1D, the NOD mouse, regulatory T-cells are able to protect 
from diabetes (Peng et al. 2004; Masteller et al. 2005).  In mice it was also shown 
that regulatory T-cells are present in insulitis and their protective effect is dependent 
on the expression of ICOS (Herman et al. 2004). In human studies no difference in 
the frequency of regulatory T-cells between patients with T1D and unaffected 
controls was reported (Brusko et al. 2005; Lindley et al. 2005; Putnam et al. 2005). 
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Two of those studies, however, suggested that the regulatory T-cells of patients with 
T1D have a defective ability to suppress T-cell proliferation in in vitro proliferation 
tests (Brusko et al. 2005; Lindley et al. 2005). None, however, have addressed the 
subject of autoantigen-specific regulatory T-cells in patients with T1D. 
We used both human and bovine insulin in cell culture. Human insulin is an 
endogenous antigen and is expressed in the thymus, and thus human insulin-specific 
thymus-derived regulatory T-cells can exist. Bovine insulin is encountered in the 
diet and putative bovine insulin-specific regulatory T-cells are peripherally induced 
to exogenous antigen. Human and bovine insulin differ by only three amino acids 
and their immunological responses often cross-react, although bovine insulin is a 
stronger immunogen. In this publication human and bovine insulin-induced 
expressions of regulatory T-cell markers correlated with each other, but differences 
in the characteristics of Foxp3 mRNA expression were also found.  Human insulin-
induced expression of Foxp3 mRNA levels correlated inversely with HbA1c values 
detected 5-6 months after diagnosis, but bovine insulin-induced Foxp3 mRNA levels 
were directly correlated with HbA1c values. Bovine insulin-induced Foxp3 
expression also correlated with the proliferative response induced by bovine insulin, 
which could not be found after human insulin stimulation. These correlations 
suggest that human insulin stimulation induces an increase in regulatory T-cells that 
are able to suppress human insulin-specific effector T-cells, and regulatory T-cells 
activated by insulin treatment may explain the remission period seen in many newly 
diagnosed T1D children after beginning insulin treatment. However, the bovine 
insulin-induced responses observed in this study did not appear to suppress effector 
T-cells and bovine insulin could have induced more of an effector T-cell response 
than a regulatory T-cell response or the bovine insulin-specific peripherally induced 
regulatory T-cells may have had functional defects. 
We also showed that both groups of T1D patients, both before and after initiating 
insulin treatment, showed increased IL-4 expression in response to insulin 
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stimulation. Insulin treatment, however, appeared to enhance the IL-4 response. 
Interestingly, IL-4 activates regulatory T-cells (Maerten et al. 2005). Both the 
increased regulatory T-cell marker and IL-4 expressions in response to in vitro
insulin stimulation in newly diagnosed patients may explain the difficulties in 
developing T1D-associated autoantigen-specific T-cell assays. Likewise, we found 
no differences in T-cell proliferation between children with T1D and the unaffected 
controls. The mRNA expression levels of IL-4 and TGF-β mRNAs, both cytokines 
known to inhibit T-cell proliferation, correlated with the IAA levels of the patients 
after human insulin stimulation. Furthermore, the IAA levels correlated inversely 
with the human insulin-induced T-cell proliferation response. This finding suggests 
that patients with recent-onset T1D have a Th2 type of immune response to insulin 
associated with IAAs, and the in vitro proliferation of T-cells is down-regulated due 
to the existence of this Th2 response. 
The increased IL-4 expression in response to insulin is in agreement with animal 
studies showing that insulin aerosol treatment in NOD mice induces the formation 
of insulin antibodies and increases IL-4 secretion from splenocytes (Harrison et al. 
1996). Subcutaneous insulin immunization in NOD mice also increases the 
frequency of IL-4-secreting insulin-specific T-cells and inhibits the proliferative 
response of T-cells (Tian et al. 1998), while oral insulin treatment in NOD mice up-
regulates the amount of IL-4-secreting cells in the pancreatic islets (Ploix et al. 
1998). In humans it was shown that intranasal insulin induces increased antibody 
formation and inhibits the insulin-specific cellular immune response in 
autoantibody-positive children at risk for T1D (Harrison et al. 2004) and that insulin 
treatment shifts the insulin antibody response one predominantly of an IgG1 
subclass to a Th2-specific IgG4 subclass (Füchtenbusch et al. 2000). 
In the present study the insulin-induced enhanced Th2 type of immune response 
conflicts with the concept of T1D as a Th1-mediated disease, but agrees with the 
observation of IL-13-secreting insulin-specific T-cell lines derived from the 
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pancreatic lymph nodes of patients with T1D (Kent et al. 2005). The insulin-induced 
increase in IL-4 expression also accords with previous publications reporting that 
stimulated CD4+ T-cells secrete IL-4 and IL-10 in response to preproinsulin 
epitopes in individuals with T1D-associated autoantibodies (Durinovic-Bellò et al. 
2004) and that insulin increases mitogen-induced secretion of IL-4 from PBMCs 
(Kretowski et al. 1999). In addition, the occurrence of IgG4 subclass IAAs in 
nondiabetic autoantibody-positive children fits well with our finding, since IL-4 
supports formation of IgG4 subclass (Bonifacio et al. 1999). It was suggested that 
the presence of autoantibodies of the IgG1 subclass represents a low predictive value 
for T1D but the disease risk increases when the humoral immune response to 
autoantigens spreads to include the IgG2 and IgG4 subclasses (Achenbach et al. 
2004). Thus, the increase in IL-4 expression in response to insulin suggests that the 
Th2 type of immune response is also involved in the autoimmune response to 
endogenous insulin in patients with T1D. 
6.3 Breast milk insulin promotes oral tolerance to dietary insulin (III) 
Insulin is present in breast milk in various species (Kulski and Hartmann 1983; 
Aranda et al. 1991). We demonstrated that in mothers suffering from T1D the level 
of insulin in breast milk is higher than in unaffected mothers, which is in agreement 
with previous results (Jovanovic-Peterson et al. 1989). Patients with T1D use daily 
insulin injections and their plasma insulin levels are often increased, which probably 
reflects the concentration of insulin in their breast milk. Due to human insulin 
treatment, most of the insulin detected in breast milk is most likely of human origin. 
We also found that the concentrations of insulin in breast milk were inversely 
associated with the humoral immune response to bovine insulin. We showed earlier 
that hydrolyzed casein-based infant formula does not induce as high levels of IgG 
antibodies to insulin as regular cow’s milk-based formula (Vaarala et al. 1999; 
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Paronen et al. 2000). Indeed, at 6 months of age the inverse association between 
breast milk insulin and bovine insulin-specific antibodies was detected only in the 
group of children who were exposed to intact cow’s milk proteins in the diet and not 
in the group of children receiving hydrolyzed casein-based formula. Later, at 12 
months of age, the inverse correlation was found in both groups of children in the 
trial because at that age all the children had received cow’s milk after the 
intervention period. Our finding suggests that human insulin present in breast milk 
induces tolerance to dietary bovine insulin. When an infant is exposed to cow’s milk 
insulin an immune response to bovine insulin is developed and this response may be 
down-regulated with human insulin in breast milk. 
It is true that bovine and human insulin crossreact in insulin antibody ELISA and as 
shown by Vaarala et al. (1999) the immune responses to bovine and human insulin 
measured using ELISA correlate. However, the insulin antibody titers are shown to 
increase when children are exposed to cow’s milk in their diet, and thus the ELISAs 
measure largely insulin antibodies to dietary bovine insulin. 
It was previously shown that the infants of diabetic mothers have decreased insulin-
specific immunity (Paronen et al. 2000) and the risk of T1D is lower in the children 
of diabetic mothers than diabetic fathers (Warram et al. 1984), and these two 
phenomena could be explained by this tolerogenic effect of breast milk insulin. On 
the other hand, mother’s diabetes may affect child’s insulin-specific immune 
responses in some other way than by increasing insulin concentration in breast milk, 
for example the fluctuations of mother’s blood glucose may stimulate fetal insulin 
production, which could affect immune responses to insulin. 
Interestingly, those children in the present study who later developed T1D-associated 
autoantibodies behaved differently. The insulin levels in breast milk of the mothers of 
these children were increased. Perhaps in these children, who were prone to β-cell 
autoimmunity, the breast milk insulin did not induce tolerance. The derangements in 
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the gut immune system suggested to be involved in the pathogenesis of T1D may 
explain the impairment of developing oral tolerance to insulin. 
6.4  Immunological changes in the small intestine of children with 
type 1 diabetes (IV) 
The increased mRNA expression levels of IL-18 in duodenal biopsies were strongly 
associated with T1D patients who showed no signs of celiac disease. The level of 
IL-18 mRNA was even lowered in patients with celiac disease or potential celiac 
disease compared with the control group with normal mucosae. The increased 
expression of regulatory T-cell marker Foxp3 and the cytokines IL-10 and IFN-Ȗ,
and CD25 were associated with celiac disease and the expression of these markers 
was not altered in pediatric patients with T1D. 
Both activated macrophages and intestinal epithelial cells are able to produce IL-18 
in the gut. A previous finding of increased IL-1α expression in the gut of patients 
with T1D (Westerholm-Ormio et al. 2003) fits well with this, since both of these 
cytokines are expressed by activated macrophages. IL-18 is at some level normally 
expressed in the gut (Takeuchi et al. 1997; Salvati et al. 2002), but its increase was 
associated with some intestinal disorders such as Crohn´s disease (Monteleone et al. 
1999; Pizarro et al. 1999). 
In animal studies IL-18 was expressed during the course of insulitis in pancreatic 
islets (Hong et al. 2000; Frigerio et al. 2002). IL-18 inhibitor is also able to delay the 
development of an accelerated form of diabetes in NOD mice (Zaccone et al. 2005). 
In humans the presence of T1D-associated autoantibodies, especially multiple 
autoantibodies, is associated with an increased level of circulating IL-18 (Nicoletti et 
al. 2001; Hanifi-Moghaddam et al. 2003). Polymorphisms in the promoter of the IL-
18 gene may also be associated with susceptibility to T1D (Kretowski et al. 2002; 
Ide et al. 2004). 
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IL-18 is known to affect the induction of oral tolerance and it was shown that the 
induction of oral tolerance can be abrogated by administration of IL-18 and IL-12 in 
mice (Eaton et al. 2003). This suggests that the increased IL-18 expression in the gut 
of patients with T1D may be involved in the impaired induction of oral tolerance, 
which could explain the enhanced immune response to dietary proteins found in 
patients with T1D. Unfortunately, immunohistochemical staining for IL-18 was not 
done in our patient samples. The expression detected only at the mRNA level does 
not prove the existence of the protein. However, this finding of increased IL-18 
mRNA expression in the gut of patients with T1D supports the theory that the gut 
immune system is involved in the pathogenesis of T1D. 
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7 CONCLUSIONS
I In the first publication we showed that IAAs measured from plasma or serum may 
result in a substantial proportion of false-negative results. When the IAAs were 
detected in the isolated IgG fraction instead, as many as half of the T1D patients 
negative for IAAs became positive for IAAs. This finding may have been due to the 
formation of insulin-IAA immune complexes or some other unspecified factor 
present in plasma, and either the immune complexes or this factor could have been 
eliminated during the isolation of IgG. 
II We found increased expression of regulatory T-cell markers in response to in 
vitro insulin (both human and bovine insulin) stimulation. This was only seen in 
recent-onset T1D children treated with insulin and not before initiating insulin 
treatment. Since the T1D-unrelated control antigen showed no similar findings and 
similar differences between the treated and untreated patients could not be seen in 
the other markers measured, we conclude that insulin treatment in children with 
recent-onset T1D stimulates insulin-specific regulatory T-cells in vivo. Regulatory 
T-cells induced by insulin treatment may explain the remission period often seen in 
newly diagnosed children after beginning the insulin treatment. 
Furthermore, we found that in vitro insulin stimulation resulted in increased insulin-
specific IL-4 expression in children with T1D both before and after initiating insulin 
treatment, which suggests that the immune response to endogenous insulin also 
involves the Th2 type of response in patients with T1D. Both insulin-induced increase 
in regulatory T-cells and increased Th2 immune response may explain the difficulties 
in studying insulin-specific T-cell responses in newly diagnosed T1D patients. 
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III Third publication showed that the insulin content in the mother’s breast milk 
modulates the humoral immune response to dietary insulin in the offspring. The high 
concentration of insulin in breast milk was associated with low levels of bovine 
insulin-specific antibodies in children, suggesting that human insulin in breast milk 
may promote tolerance to bovine insulin received from the diet. This finding may 
explain why the risk of T1D is lower in the children of mothers with T1D than in 
children of fathers with T1D. 
However, in those children who later developed ȕ-cell autoimmunity expressed as 
T1D-associated autoantibodies, the concentration of insulin in the mothers´ breast 
milk was significantly higher than in other children. This may indicate that children 
prone to ȕ-cell autoimmunity cannot promote oral tolerance to dietary insulin, 
perhaps due to immunological derangements in their gut immune systems. 
IV In the fourth publication the expression of IL-18 mRNA was clearly increased in 
small intestinal biopsies of children with T1D and this increment was not associated 
with celiac disease or potential celiac disease. In contrast, celiac disease appeared to 
lower the expression level of IL-18. Expression of IL-18 is a marker for immune 
activation in the gut and may be involved, among other things, in the development 
of oral tolerance. However, this finding lends further support for the hypothesis that 
changes in the gut immune system may play a role in the pathogenesis of T1D. 
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